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Abstract
Background:  Carcinoma of the esophagus is an aggressive malignancy with an increasing
incidence. Its virulence, in terms of symptoms and mortality, justifies a continued search for optimal
therapy. A clinical practice guideline was developed based on a systematic review investigating
neoadjuvant or adjuvant therapy on resectable thoracic esophageal cancer.
Methods: A systematic review with meta-analysis was developed and clinical recommendations
were drafted. External review of the practice guideline report by practitioners in Ontario, Canada
was obtained through a mailed survey, and incorporated. Final approval of the practice guideline
was obtained from the Practice Guidelines Coordinating Committee.
Results: The systematic review was developed and recommendations were drafted, and the
report was mailed to Ontario practitioners for external review. Ninety percent of respondents
agreed with both the evidence summary and the draft recommendations, while only 69% approved
of the draft recommendations as a practice guideline. Based on the external review, a revised
document was created. The revised practice guideline was submitted to the Practice Guidelines
Coordinating Committee for review. All 11 members of the PGCC returned ballots. Eight PGCC
members approved the practice guideline report as written and three members approved the
guideline conditional on specific concerns being addressed. After these recommended changes
were made, the final practice guideline report was approved.
Conclusion: In consideration of the systematic review, external review, and subsequent Practice
Guidelines Coordinating Committee revision suggestions, and final approval, the Gastrointestinal
Cancer Disease Site Group recommends the following:
For adult patients with resectable thoracic esophageal cancer for whom surgery is considered 
appropriate, surgery alone (i.e., without neoadjuvant or adjuvant therapy) is recommended as the 
standard practice.
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Background
Carcinoma of the esophagus is an aggressive malignancy
with an increasing incidence. Its virulence, in terms of
symptoms and mortality, justifies a continued search for
optimal therapy. The large and growing number of
patients affected, the high mortality rates, the worldwide
geographic variation in practice, and the large body of
good quality research warrants a clinical practice guide-
line.
This clinical practice guideline was developed by the Gas-
trointestinal Cancer Disease Site Group (DSG) of Cancer
Care Ontario's Program in Evidence-based Care (PEBC),
using the methods of the Practice Guidelines Develop-
ment Cycle [1]. This practice guideline report is a conven-
ient and up-to-date source of the best available evidence
on neoadjuvant or adjuvant therapy for resectable esopha-
geal cancer, developed through systematic review, evi-
dence synthesis, and input from practitioners in Ontario.
The PEBC has a formal standardized process to ensure the
currency of each clinical practice guideline report. This
process consists of the periodic review and evaluation of
the scientific literature and, where appropriate, integra-
tion of this literature with the original clinical practice
guideline information.
The systematic review on neoadjuvant or adjuvant therapy
for resectable esophageal cancer, which forms the basis for
this clinical practice guideline, is available in a compan-
ion document [2]. Based on the systematic review, draft
recommendations were developed by consensus of the
Gastrointestinal Cancer DSG to create the clinical practice
guideline report. The clinical practice guideline is
intended to promote evidence-based practice in Ontario,
Canada. As part of the PEBC's clinical Practice Guideline
Development Cycle, all draft recommendations are sent
to Ontario practitioners for external review. The efficacy of
this external review process has been previously described
[3]. The external review is a mailed survey consisting of
items that address the quality of the draft practice guide-
line report and draft recommendations and whether the
draft recommendations should serve as a practice guide-
line. Final approval of this practice guideline report was
obtained from the Practice Guidelines Coordinating
Committee (PGCC).
Methods
Clinical practice guideline development
Systematic review
A systematic review with meta-analysis on neoadjuvant or
adjuvant therapy for resectable esophageal cancer was
developed by the Gastrointestinal Cancer DSG of Cancer
Care Ontario's Program in Evidence-based Care [2]. The
evidence examined did not support the use of neoadju-
vant or adjuvant chemotherapy or radiotherapy for resect-
able thoracic esophageal cancer.
Gastrointestinal cancer disease site group consensus
In discussions regarding the completed systematic review,
the Gastrointestinal Cancer DSG agreed that the evidence
did not support a recommendation for neoadjuvant or
adjuvant chemotherapy or radiotherapy for resectable
thoracic esophageal cancer. A recommendation that sur-
gery alone should be the standard of care for this patient
population was drafted, and it was recommended that the
draft practice guideline be sent out to Ontario practition-
ers for external review.
The role of radiotherapy alone and chemoradiation alone
without surgery is addressed in a separate Gastrointestinal
Cancer DSG Clinical Practice Guideline: Combined modal-
ity radiotherapy and chemotherapy in the non-surgical man-
agement of localized carcinoma of the esophagus [4].
Results
External review
Practitioner feedback was obtained through a mailed sur-
vey of 163 practitioners in Ontario (27 medical oncolo-
gists, 21 radiation oncologists, 112 surgeons, and three
gastroenterologists). The survey consisted of items evalu-
ating the methods, results, and interpretative summary
used to inform the draft recommendations and whether
the draft recommendations should be approved as a prac-
tice guideline. Written comments were invited. Follow-up
reminders were sent at two weeks (post card) and four
weeks (complete package mailed again). The Gastrointes-
tinal Cancer DSG reviewed the results of the survey.
Eighty-six surveys (58%) were returned. Twenty-nine
respondents (34%) (nine medical oncologists, seven radi-
ation oncologists, and 13 surgeons) indicated that the
report was relevant to their clinical practice and com-
pleted the survey. Key results of the practitioner feedback
survey are summarized below.
1. Number surveyed: 163 practitioners in Ontario, Can-
ada involved in the care of cancer patients
2. Return rate: 58% (mean Gastrointestinal Cancer DSG
return rate: 60.2%; range: 51% – 84%)
3. Written comments attached: 10%
4. Agreement with the summary of evidence: 90%
5. Agreement with the recommendation: 90%
6. Approval of the recommendation as a practice guide-
line: 69%BMC Cancer 2004, 4:67 http://www.biomedcentral.com/1471-2407/4/67
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Summary of main findings
Three (10%) respondents provided written comments.
One practitioner hypothesized that preoperative chemo-
radiation might have a role in adenocarcinoma of the
lower third of the esophagus (as suggested by Walsh et al
[5] with 100% adenocarcinoma and by Urba et al [6] with
75% adenocarcinoma), but not in squamous cell carci-
noma (as suggested by Bosset et al [7] and by Le Prise et al
[8]). Another respondent noted that the survival advan-
tage at three years for combined treatment for preopera-
tive chemoradiotherapy is discounted in the guideline
report, and suggested that the guideline recommend the
selection of the option preferred by informed patients.
There was a request for an algorithm to help in deciding
between surgical and non-surgical treatment. The same
respondent commented on the limited discussion on
quality of life. Two radiation oncologists disagreed with
the recommendations and thought that the draft practice
guideline report should not be approved as a practice
guideline, but neither provided written comments.
Discussion
Gastrointestinal cancer disease site group modifications 
and actions
After completion of the practitioner feedback survey,
additional trials were found. The results of two rand-
omized trials both found surgery alone to be significantly
superior to radiation alone [9,10], which resulted in an
original draft recommendation regarding radiation alone
as a primary modality for localized esophageal cancer
being removed from the final practice guideline.
In response to this feedback, the Gastrointestinal Cancer
DSG acknowledged that the majority of studies have been
performed in squamous cell carcinomas. While adenocar-
cinomas were included in some studies, a distinction
between the two histological subtypes was not made
because previous studies have not consistently found that
they respond differently to chemotherapy or radiation,
and nine references [11-19] were added to support this.
The Gastrointestinal Cancer DSG did not feel the evidence
was compelling enough to recommend preoperative
chemoradiotherapy over surgery alone based on the three-
year data. After consideration, the Gastrointestinal Cancer
DSG decided not to create an algorithm as suggested as a
similar project is currently under development.
After addressing the comments obtained from practition-
ers during the external review, the Gastrointestinal Cancer
DSG voted that the overall guideline recommendations
should be approved, and submitted the practice guideline
to the Practice Guidelines Coordinating Committee for
review.
Practice guidelines coordinating committee approval 
process
The practice guideline report was circulated to members
of the Practice Guidelines Coordinating Committee for
review and approval. All 11 members of the PGCC
returned ballots. Eight PGCC members approved the
practice guideline report as written and three members
approved the guideline conditional on the Gastrointesti-
nal Cancer DSG addressing specific concerns. PGCC
members requested that the following issues be addressed
prior to the approval of the guideline report:
One member noted that although the majority of studies
had been performed in squamous cell carcinomas, some
studies included adenocarcinomas, and it would be help-
ful if the pathological subtypes were discussed. In particu-
lar, this member wanted to know if there was any
difference in response or outcome for the two histological
subtypes. Another member noted that although the
pooled analysis for preoperative chemoradiation versus
surgery alone detected no difference at one year, the
pooled estimate almost reached significance. This mem-
ber was concerned that the discussion may be too dismiss-
ive of the data, and suggested there be some
acknowledgment that further follow-up and additional
studies are needed.
In response to this feedback, the Gastrointestinal Cancer
DSG expanded on the earlier revisions concerning the
similarities in response to treatment between squamous
cell carcinomas and adenocarcinomas.
Also, after the original practice guideline was submitted to
the PGCC, two meta-analyses [20,21] both detecting a sta-
tistically significant difference in survival at three years
favouring preoperative chemoradiation versus surgery
alone were obtained. The Gastrointestinal Cancer DSG re-
pooled the mortality data from the six trials [5-8,22,23] at
three years and obtained similar results.
Conclusions
In consideration of the systematic review, external review,
and subsequent Practice Guidelines Coordinating Com-
mittee revision suggestions, and final approval, the Gas-
trointestinal Cancer Disease Site Group developed the
following Clinical Practice Guideline:
Practice guideline
This practice guideline reflects the most current informa-
tion reviewed by the Gastrointestinal Cancer DSG.
Target population
These recommendations apply to adult patients with
resectable and potentially curable thoracic (lower two-BMC Cancer 2004, 4:67 http://www.biomedcentral.com/1471-2407/4/67
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thirds of esophagus) esophageal cancer for whom surgery
is considered appropriate.
Recommendation
• If surgery is considered appropriate, then surgery alone
(i.e., without neoadjuvant or adjuvant therapy) is recom-
mended as the standard practice for resectable thoracic
esophageal cancer.
This Clinical Practice Guideline report is based on work
completed in October, 2003. All approved PEBC Clinical
Practice Guideline reports are updated regularly. Please
see the PEBC's web site http://www.cancercare.on.ca/
access_PEBC.htm for a complete list of current and on-
going projects.
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